Your AI-Trained Oncology Knowledge Connection!
Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.
Acalabrutinib demonstrated a favorable risk-benefit profile in R/R CLL.
Compared with ibrutinib, acalabrutinib demonstrates less toxicity burden In CLL.
Magrolimab will be tested in combination with various antileukemia therapies at multiple disease points, such as the first line and remission stages.
Early study results indicate that YTB323 may be effective and safe for the treatment of patients with diffuse large B-cell lymphoma.
Venetoclax dosed at either 400 mg or 800 mg in combination with daratumumab and dexamethasone showed promising preliminary results in a phase 1/2 study.
In the MEDALIST analysis that was presented at the 2021 ASH Annual Meeting, investigators sought to further characterize the effects of luspatercept in patients with low-risk myelodysplastic syndrome.
Having knowledge that their multiple myeloma was incurable was associated with poor quality of life outcomes in patients.
The XVd regimen appears effective at prolonging progression-free survival with decreased toxicity when administered at lower doses of selinexor or the standard dose.
Polatuzumab vedotin-piiq added to the R-CHOP regimen elicited a high progession-free survival rate in patients with newly-diagnosed diffuse large B-cell lymphoma.
Updated results from CARTITUDE-1 reveal deep and durable response to ciltacabtagene autoleucel treatment in patients with multiple myeloma.
Preliminary results from the phase 2 ERADIC trial signal promise for ibrutinib plus venetoclax for the treatment of chronic lymphocytic leukemia.
An early and deep response was seen with a single infusion of cilta-cel in patients with multiple myeloma who experienced early clinical relapse.
A more durable and deep responses was produced with the recommended phase 2 dose of selinexor plus pomalidomide and dexamethasone compared with the lesser selinexor dose for relapsed or refractory multiple myeloma.
While Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma, adverse events were common in some of these populations.
In patients with relapsed/refractory multiple myeloma with t(11;14), Selinexor plus venetoclax induced decreases in cyclin D1, XPO1, and MCL-1.
Compared to those who received rituximab and bendamustine, elderly patients treated with ibrutinib-containing regimens for chronic lymphocytic leukemia saw a progression-free survival benefit.
Durable responses and tolerability for patients was seen with itolizumab for acute graft-versus-host disease.
Lisocabtagene maraleucel treatment in patients with relapsed or refractory B-cell lymphoma achieves long-lasting responses, study shows.
The costs of treatment and time spent managing adverse effects varied significantly in patients with chronic lymphocytic leukemia treated with acalabrutinib, ibrutinib, and venetoclax.
Jennifer R. Brown, MD, PhD, discusses the implications of the SEQUOIA trial, which looked at the combination of zanubrutinib and venetoclax for the treatment of patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.
The efficacy and safety of naratuximab emtansine plus rituximab appear impressive for patients with B-cell non-Hodgkin lymphomas who are ineligible for stem cell transplant or chimeric antigen receptor T-cell therapy.
Undetectable minimal residual disease may be achieved with time-limited ublituximab and umbralisib added to ibrutinib in patients with chronic lymphocytic leukemia.
Phase 3 ZUMA-7 study results indicate that axicabtagene ciloleucel may achieve longer event-free survival compared with standard chemotherapy.
A CARTITUDE-1 meta-analysis data shows that ciltacabtagene autoleucel performs better than standard-of-care therapy in terms of survival and response rates in patients with triple-class relapsed/refractory multiple myeloma.
Results from the phase 2 IFM 2018-01 trial show positive safety and efficacy for the combination of daratumumab with ixazomib, lenalidomide, and dexamethasone.
Analysis shows that International Prognostic Scoring System score and the presence of a JAK2 mutation was linked to risk of thrombosis in patients with primary myelofibrosis. Investigators observed a benefit for ruxolitinib in patients.
Minimum residual disease can inform approaches to treatment of newly diagnosed multiple myeloma for patients receiving daratumumab plus carfilzomib, lenalidomide, and dexamethasone following autologous transplant.
Axicabtagene ciloleucel demonstrated a quality of life improvement in patients with large B-cell lymphoma as a second-line treatment compared with standard of care.
In a randomized phase 3 trial, acalabrutinib plus venetoclax versus obinutuzumab plus venetoclax will be investigated for efficacy and safety with a noninferiority design in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic leukemia.